{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T06:04:15Z","timestamp":1763705055090,"version":"3.40.5"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","atherosclerosis-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.atherosclerosis.2015.06.033","type":"journal-article","created":{"date-parts":[[2015,6,18]],"date-time":"2015-06-18T21:23:27Z","timestamp":1434662607000},"page":"641-648","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Lipoprotein associated phospholipase A2 activity, apolipoprotein C3 loss-of-function variants and cardiovascular disease: The Atherosclerosis Risk In Communities Study"],"prefix":"10.1016","volume":"241","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7376-8016","authenticated-orcid":false,"given":"Yashashwi","family":"Pokharel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wensheng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda M.","family":"Polfus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron R.","family":"Folsom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerardo","family":"Heiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. Richey","family":"Sharrett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Boerwinkle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christie M.","family":"Ballantyne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron C.","family":"Hoogeveen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.atherosclerosis.2015.06.033_bib1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis\u2013an inflammatory disease","volume":"340","author":"Ross","year":"1999","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2015.06.033_bib2","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1172\/JCI115499","article-title":"Role of oxidized low density lipoprotein in atherogenesis","volume":"88","author":"Witztum","year":"1991","journal-title":"J.\u00a0Clin. Invest."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2015.06.033_bib3","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1073\/pnas.82.9.3000","article-title":"Essential role of phospholipase A2 activity in endothelial cell-induced modification of low density lipoprotein","volume":"82","author":"Parthasarathy","year":"1985","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"8","key":"10.1016\/j.atherosclerosis.2015.06.033_bib4","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1073\/pnas.85.8.2805","article-title":"Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis","volume":"85","author":"Quinn","year":"1988","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2015.06.033_bib5","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1172\/JCI115932","article-title":"Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells","volume":"90","author":"Kume","year":"1992","journal-title":"J.\u00a0Clin. Invest."},{"issue":"17","key":"10.1016\/j.atherosclerosis.2015.06.033_bib6","doi-asserted-by":"crossref","first-page":"11095","DOI":"10.1016\/S0021-9258(18)99132-5","article-title":"Human plasma platelet-activating factor acetylhydrolase. Oxidatively fragmented phospholipids as substrates","volume":"266","author":"Stremler","year":"1991","journal-title":"J.\u00a0Biol. Chem."},{"issue":"11","key":"10.1016\/j.atherosclerosis.2015.06.033_bib7","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1161\/01.ATV.0000244681.72738.bc","article-title":"Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis","volume":"26","author":"Kolodgie","year":"2006","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2015.06.033_bib8","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1161\/01.ATV.16.4.591","article-title":"Purification, properties, sequencing, and cloning of a lipoprotein-associated, serine-dependent phospholipase involved in the oxidative modification of low-density lipoproteins","volume":"16","author":"Tew","year":"1996","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"7","key":"10.1016\/j.atherosclerosis.2015.06.033_bib9","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1074\/jbc.273.7.4012","article-title":"Expression of plasma platelet-activating factor acetylhydrolase is transcriptionally regulated by mediators of inflammation","volume":"273","author":"Cao","year":"1998","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2015.06.033_bib10","unstructured":"Food and Drug Administration. Web site. http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm426799.htm. Accessed April 15, 2015."},{"issue":"9725","key":"10.1016\/j.atherosclerosis.2015.06.033_bib11","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/S0140-6736(10)60319-4","article-title":"Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies","volume":"375","author":"Thompson","year":"2010","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.atherosclerosis.2015.06.033_bib12","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1056\/NEJMoa1315878","article-title":"Darapladib for preventing ischemic events in stable coronary heart disease","volume":"370","author":"White","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"10","key":"10.1016\/j.atherosclerosis.2015.06.033_bib13","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1001\/jama.2014.11061","article-title":"Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial","volume":"312","author":"O'Donoghue","year":"2014","journal-title":"JAMA J.\u00a0Am. Med. Assoc."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2015.06.033_bib14","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1056\/NEJMc1409673","article-title":"Coronary heart disease and genetic variants with low phospholipase A2 activity","volume":"372","author":"Polfus","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"15","key":"10.1016\/j.atherosclerosis.2015.06.033_bib15","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1161\/CIRCULATIONAHA.109.875807","article-title":"Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype","volume":"121","author":"Zheng","year":"2010","journal-title":"Circulation"},{"issue":"5908","key":"10.1016\/j.atherosclerosis.2015.06.033_bib16","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1126\/science.1161524","article-title":"A\u00a0null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection","volume":"322","author":"Pollin","year":"2008","journal-title":"Sci.ence (New York, N.Y.)"},{"issue":"21","key":"10.1016\/j.atherosclerosis.2015.06.033_bib17","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1001\/archinte.165.21.2479","article-title":"Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study","volume":"165","author":"Ballantyne","year":"2005","journal-title":"Arch. Intern. Med."},{"issue":"7","key":"10.1016\/j.atherosclerosis.2015.06.033_bib18","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1161\/01.CIR.0000116763.91992.F1","article-title":"Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study","volume":"109","author":"Ballantyne","year":"2004","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2015.06.033_bib19","first-page":"687","article-title":"design and objectives. The ARIC investigators","volume":"129","author":"The Atherosclerosis Risk in Communities (ARIC) Study","year":"1989","journal-title":"Am. J. Epidemiol."},{"year":"1994","series-title":"Atherosclerosis Risk in Communities Study: Manual 8: Lipid and Lipoprotein Determinations. Version 2.0 ed","author":"National Heart L, and Blood Institute","key":"10.1016\/j.atherosclerosis.2015.06.033_bib20"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2015.06.033_bib21","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin. Chem."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2015.06.033_bib22","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1161\/ATVBAHA.114.303284","article-title":"Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: the Atherosclerosis Risk In Communities (ARIC) study","volume":"34","author":"Hoogeveen","year":"2014","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2015.06.033_bib23","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1471-2105-15-30","article-title":"Launching genomics into the cloud: deployment of Mercury, a next generation sequence analysis pipeline","volume":"15","author":"Reid","year":"2014","journal-title":"BMC Bioinform."},{"issue":"11","key":"10.1016\/j.atherosclerosis.2015.06.033_bib24","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1161\/01.STR.0000035286.87503.31","article-title":"Characterization of incident stroke signs and symptoms: findings from the atherosclerosis risk in communities study","volume":"33","author":"Rathore","year":"2002","journal-title":"Stroke J. Cereb. Circ."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2015.06.033_bib25","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1161\/01.STR.30.4.736","article-title":"Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort","volume":"30","author":"Rosamond","year":"1999","journal-title":"Stroke J. Cereb. Circ."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2015.06.033_bib26","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0895-4356(95)00041-0","article-title":"Community surveillance of coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) Study: methods and initial two years' experience","volume":"49","author":"White","year":"1996","journal-title":"J.\u00a0Clin. Epidemiol."},{"issue":"2 Pt 2 Suppl.\u00a01","key":"10.1016\/j.atherosclerosis.2015.06.033_bib27","first-page":"I1","article-title":"National Institute of Neurological and Communicative Disorders and Stroke","volume":"12","author":"The National Survey of Stroke","year":"1981","journal-title":"Stroke J. Cereb. Circ."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2015.06.033_bib28","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1161\/HYPERTENSIONAHA.114.04206","article-title":"High-sensitivity troponin T and cardiovascular events in systolic blood pressure categories: atherosclerosis risk in communities study","volume":"65","author":"Pokharel","year":"2015","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2015.06.033_bib29","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ajhg.2008.06.024","article-title":"Methods for detecting associations with rare variants for common diseases: application to analysis of sequence data","volume":"83","author":"Li","year":"2008","journal-title":"Am. J. Hum. Genet."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2015.06.033_bib30","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1307095","article-title":"Loss-of-function mutations in APOC3, triglycerides, and coronary disease","volume":"371","author":"Crosby","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2015.06.033_bib31","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1093\/eurheartj\/ehr372","article-title":"Eight genetic loci associated with variation in lipoprotein-associated phospholipase A2 mass and activity and coronary heart disease: meta-analysis of genome-wide association studies from five community-based studies","volume":"33","author":"Grallert","year":"2012","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2015.06.033_bib32","doi-asserted-by":"crossref","first-page":"e1000928","DOI":"10.1371\/journal.pgen.1000928","article-title":"Genome-wide association study of Lp-PLA(2) activity and mass in the Framingham Heart Study","volume":"6","author":"Suchindran","year":"2010","journal-title":"PLoS Genet."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2015.06.033_bib33","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1308027","article-title":"Loss-of-function mutations in APOC3 and risk of ischemic vascular disease","volume":"371","author":"Jorgensen","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2015.06.033_bib34","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0022-2275(20)34342-X","article-title":"Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver","volume":"26","author":"Windler","year":"1985","journal-title":"J.\u00a0Lipid Res."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2015.06.033_bib35","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1194\/jlr.M600249-JLR200","article-title":"Dynamics of dense electronegative low density lipoproteins and their preferential association with lipoprotein phospholipase A(2)","volume":"48","author":"Gaubatz","year":"2007","journal-title":"J.\u00a0Lipid Res."},{"issue":"7404","key":"10.1016\/j.atherosclerosis.2015.06.033_bib36","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1136\/bmj.326.7404.1423","article-title":"Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis","volume":"326","author":"Law","year":"2003","journal-title":"BMJ Clin. Res. ed."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2015.06.033_bib37","doi-asserted-by":"crossref","first-page":"e000360","DOI":"10.1161\/JAHA.113.000360","article-title":"Changes in lipoprotein-Associated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: results from the Long-Term Intervention with Pravastatin in Ischemic Disease study","volume":"2","author":"White","year":"2013","journal-title":"J.\u00a0Am. Heart Assoc."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2015.06.033_bib38","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1161\/hq0202.102918","article-title":"Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB","volume":"22","author":"Tsimihodimos","year":"2002","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"10","key":"10.1016\/j.atherosclerosis.2015.06.033_bib39","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1161\/ATVBAHA.107.147280","article-title":"Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2","volume":"27","author":"Saougos","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2015.06.033_bib40","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1210\/jc.2003-031494","article-title":"Fluvastatin slow-release lowers platelet-activating factor acetyl hydrolase activity: a placebo-controlled trial in patients with type 2 diabetes","volume":"89","author":"Winkler","year":"2004","journal-title":"J.\u00a0Clin. Endocrinol. Metab."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915015013878?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915015013878?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,14]],"date-time":"2022-05-14T03:25:21Z","timestamp":1652498721000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915015013878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S0021915015013878"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2015.06.033","relation":{},"ISSN":["0021-9150"],"issn-type":[{"type":"print","value":"0021-9150"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipoprotein associated phospholipase A2 activity, apolipoprotein C3 loss-of-function variants and cardiovascular disease: The Atherosclerosis Risk In Communities Study","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2015.06.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}